Biotechnology stocks, ranked

Live ranking of 16 Biotechnology stocks by TickerMover Quant Score — a 0-100 composite of fundamentals, valuation, momentum, analyst signal, and macro regime. Click any ticker for the full breakdown.

Scores are spread about as widely as the universe overall. These are descriptive measures of the group as it stands today, not a forecast and not a recommendation.

Ticker	Grade	Score	Bottom line
ACAD ACADIA Pharmaceuticals Inc.	A	77	Top-tier setup — 33% net margin. Momentum, fundamentals and macro indicators are aligned.
HALO Halozyme Therapeutics, Inc.	A	75	Top-tier setup — 48% revenue growth, +26% 30-day momentum, 3/4 EPS beats. Caveat: trades 5.5% above analyst mean target. Stock is trading above the analyst mean target ($100) — limited consensus headroom.
CORT Corcept Therapeutics Incorporated	A	75	Top-tier setup — 32% revenue growth. Momentum, fundamentals and macro indicators are aligned.
INCY Incyte Corporation	A	75	Top-tier setup — 38% revenue growth, 3/4 EPS beats, 28% net margin. Momentum, fundamentals and macro indicators are aligned.
ARWR Arrowhead Pharmaceuticals, Inc.	A	73	Top-tier setup — 171% revenue growth. Momentum, fundamentals and macro indicators are aligned.
VRTX Vertex Pharmaceuticals Incorporated	A	72	Top-tier setup — +12% 30-day momentum, 35% net margin. Momentum, fundamentals and macro indicators are aligned.
BMRN BioMarin Pharmaceutical Inc.	A	72	Setup looks favourable on the available data. Momentum, fundamentals and macro indicators are aligned.
REGN Regeneron Pharmaceuticals, Inc.	A	71	Top-tier setup — 4/4 EPS beats, 28% net margin. Momentum, fundamentals and macro indicators are aligned.
KRYS Krystal Biotech, Inc.	A	69	Top-tier setup — 24% revenue growth, 3/4 EPS beats, 55% net margin. Momentum, fundamentals and macro indicators are aligned.
ADMA ADMA Biologics, Inc.	B	66	Solid setup — 3/4 EPS beats, 33% net margin. Momentum, fundamentals and macro indicators are aligned.
TECH Bio-Techne Corporation	B	65	Setup looks favourable on the available data. Caveat: trades 2.2% above analyst mean target. Stock is trading above the analyst mean target ($71) — limited consensus headroom.
JAZZ Jazz Pharmaceuticals plc	B	64	Solid setup — 3/4 EPS beats, 20% net margin. Momentum, fundamentals and macro indicators are aligned.
EXEL Exelixis, Inc.	B	62	Solid setup — 4/4 EPS beats, 35% net margin. Caveat: trades 2.7% above analyst mean target. Stock is trading above the analyst mean target ($53) — limited consensus headroom.
MRNA Moderna, Inc.	C	58	Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
ROIV Roivant Sciences Ltd.	C	55	Mixed signals — neither side has the edge here. The thesis lacks a clear edge from current data.
CYTK Cytokinetics, Incorporated	D	48	Risk is rising; momentum is fading or fundamentals are weakening. Multiple risk indicators are firing.

Quant Scores update every 5 minutes during US market hours. Grades: A Top Tier · B Quality · C Average · D Below Avg · F Weak. (Quality descriptors, not buy/sell recommendations.)